Synapse - Advanced Practice Providers

Results (95)

Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma

Journal Article

Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation

Meeting Abstract

Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
Blood (2024)

Fulltext@MSK | Save

Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma

Meeting Abstract

Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
Blood (2024)

Fulltext@MSK | Save

Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

Journal Article

Howard, A. J.; Concepcion, I.; Wang, A. X.; Hamadeh, I. S.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Korde, N.; Lesokhin, A. M.; Hassoun, H.; more...
Blood Advances (2024)

Fulltext@MSK | Save

A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2

Meeting Abstract

Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
Blood (2023)

Fulltext@MSK | Save

Low target antigen expression mediates resistance to BCMA CAR T cell therapy

Meeting Abstract

Perica, K.; Nataraj, S.; Sjojstrand, M. L.; Nagel, K.; Pavkovic, E.; Payson, E.; Cuenca, A.; Patel, A.; Chung, D.; Mailankody, S.; more...
Blood (2023)

Fulltext@MSK | Save

Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma

Meeting Abstract

Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
Blood (2023)

Fulltext@MSK | Save

PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma

Meeting Abstract

Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma

Meeting Abstract

Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save